|Bid||32.74 x 800|
|Ask||32.74 x 800|
|Day's Range||32.39 - 33.00|
|52 Week Range||24.27 - 45.35|
|Beta (3Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The collaboration is expected to save one Tennessee health system more than $1 million in the next five years.
CEO of Acadia Healthcare Co Inc (30-Year Financial, Insider Trades) Debra K Osteen (insider trades) bought 20,000 shares of ACHC on 09/05/2019 at an average price of $26.53 a share. Continue reading...
Acadia Healthcare (ACHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
One of Nashville’s newest duos broke ground Tuesday on a project that could create as many as 300 jobs. Ascension Saint Thomas and Acadia Healthcare are beginning construction on their $32 million, 76-bed behavioral health center in MetroCenter. The facility will be Saint Thomas’ first in Middle Tennessee dedicated solely to mental health.
How much are employees worth, in profit dollars, to some of the state's largest companies? It runs the gamut from $1,200 to more than $237,000 per employee.
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 3.39% and -1.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
A 2018 Transparency Market Research report found approximately 242 companies competing in the addiction treatment space.
Acadia Healthcare (ACHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.
Acadia Healthcare (ACHC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.